Literature DB >> 15756584

Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: a prospective study in patients with hematological malignancies.

Corrado Girmenia1, Giuseppe Cimino, Francesca Di Cristofano, Alessandra Micozzi, Giuseppe Gentile, Pietro Martino.   

Abstract

OBJECTIVE: Several studies have suggested that hydration and sodium load might reduce nephrotoxicity related to amphotericin B-deoxycholate (AmB-d). However, a schedule of these nephroprotective measures has not been standardized until now. A protocol of hydration and electrolyte supplementation was used prospectively in patients with hematological malignancies receiving empirical AmB-d treatment to evaluate its effect on AmB-d-related renal toxicity. PATIENTS AND METHODS: A total of 77 consecutive patients received AmB-d (1 mg/kg per day) in association with an initial intravenous hydration of at least 1 l/m2 body surface, containing at least 1 l of 0.9% saline daily. Hydration was increased when serum creatinine levels showed a 20% increase from baseline. Serum electrolytes were replaced when indicated.
RESULTS: The median duration of AmB-d therapy was 14 days. The mean intravenous hydration and the mean diuresis were 1530 and 1970 ml/m2 of body surface per day, respectively. Overall, 55 patients (71.4%) received a mean of 18.5 days of therapy without dose-limiting adverse events. Despite significant increases in mean creatinine serum levels and decreases in mean creatinine clearance observed early in the whole population, in only six patients (7.8%) was therapy discontinued due to renal failure, which always recovered after treatment discontinuation. In eight patients (10.4%) therapy was stopped due to infusion-related side effects. Seven patients died while under antifungal therapy without relevant signs of AmB-d-associated toxicity.
CONCLUSIONS: Our prospective experience confirms that adequate hydration (about 1500 ml/m2 of body surface) and careful electrolyte supplementation are simple measures able to contain nephrotoxicity and to permit adequate antifungal therapy at least in the empirical setting.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15756584     DOI: 10.1007/s00520-005-0783-x

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  31 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

2.  Nephrotoxicity of amphotericin B desoxycholate.

Authors:  C Girmenia; G Gentile; A Micozzi; P Martino
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

3.  Risk factors for nephrotoxicity associated with conventional amphotericin B therapy.

Authors:  Corrado Girmenia; Giuseppe Cimino; Alessandra Micozzi; Giuseppe Gentile; Pietro Martino
Journal:  Am J Med       Date:  2002-09       Impact factor: 4.965

4.  Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity.

Authors:  Stephan Harbarth; John P Burke; James F Lloyd; R Scott Evans; Stanley L Pestotnik; Matthew H Samore
Journal:  Clin Infect Dis       Date:  2002-12-02       Impact factor: 9.079

5.  Risk factors for amphotericin B-induced nephrotoxicity.

Authors:  A D Luber; L Maa; M Lam; B J Guglielmo
Journal:  J Antimicrob Chemother       Date:  1999-02       Impact factor: 5.790

6.  Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Authors:  T J Walsh; R W Finberg; C Arndt; J Hiemenz; C Schwartz; D Bodensteiner; P Pappas; N Seibel; R N Greenberg; S Dummer; M Schuster; J S Holcenberg
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

Review 7.  Amphotericin B nephrotoxicity.

Authors:  R Sabra; R A Branch
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

8.  Amphotericin B nephrotoxicity in humans decreased by salt repletion.

Authors:  H T Heidemann; J F Gerkens; W A Spickard; E K Jackson; R A Branch
Journal:  Am J Med       Date:  1983-09       Impact factor: 4.965

9.  Amphotericin B: time for a new "gold standard".

Authors:  Luis Ostrosky-Zeichner; Kieren A Marr; John H Rex; Stuart H Cohen
Journal:  Clin Infect Dis       Date:  2003-07-22       Impact factor: 9.079

10.  Sodium protects against nephrotoxicity in patients receiving amphotericin B.

Authors:  R S Stein; J A Alexander
Journal:  Am J Med Sci       Date:  1989-11       Impact factor: 2.378

View more
  7 in total

Review 1.  Treatment principles for Candida and Cryptococcus.

Authors:  Laura C Whitney; Tihana Bicanic
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

Review 2.  Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy.

Authors:  Peter R Williamson; Joseph N Jarvis; Anil A Panackal; Matthew C Fisher; Síle F Molloy; Angela Loyse; Thomas S Harrison
Journal:  Nat Rev Neurol       Date:  2016-11-25       Impact factor: 42.937

Review 3.  Fungal infections of the CNS: treatment strategies for the immunocompromised patient.

Authors:  Katharine E Black; Lindsey R Baden
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

4.  Use of Fungal Diagnostics and Therapy in Pediatric Cancer Patients in Resource-Limited Settings.

Authors:  Sheena Mukkada; Jeannette Kirby; Nopporn Apiwattanakul; Randall T Hayden; Miguela A Caniza
Journal:  Curr Clin Microbiol Rep       Date:  2016-04-18

5.  Acute Kidney Injury and Urinary Biomarkers in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis.

Authors:  Charlotte Schutz; David R Boulware; Katherine Huppler-Hullsiek; Maximilian von Hohenberg; Joshua Rhein; Kabanda Taseera; Friedrich Thienemann; Conrad Muzoora; David B Meya; Graeme Meintjes
Journal:  Open Forum Infect Dis       Date:  2017-06-20       Impact factor: 3.835

6.  Association between fluid infusions and the recovery from acute kidney injury in patients administered liposomal amphotericin B: a nationwide observational study.

Authors:  Masato Tashiro; Yoko Obata; Takahiro Takazono; Yuki Ota; Tomotaro Wakamura; Yui Shiozawa; Ai Tsuyuki; Taiga Miyazaki; Tomoya Nishino; Koichi Izumikawa
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

7.  Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis.

Authors:  Tihana Bicanic; Christian Bottomley; Angela Loyse; Annemarie E Brouwer; Conrad Muzoora; Kabanda Taseera; Arthur Jackson; Jacob Phulusa; Mina C Hosseinipour; Charles van der Horst; Direk Limmathurotsakul; Nicholas J White; Douglas Wilson; Robin Wood; Graeme Meintjes; Thomas S Harrison; Joseph N Jarvis
Journal:  Antimicrob Agents Chemother       Date:  2015-09-08       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.